Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Everolimus for compassionate use in multiple Basal cell carcinomas.

Eibenschutz L, Colombo D, Catricalà C.

Case Rep Dermatol Med. 2013;2013:604301. doi: 10.1155/2013/604301. Epub 2013 Sep 23.

2.

Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.

Tillman DK Jr, Carroll MT.

Cutis. 2007 Mar;79(3):241-8.

PMID:
17674590
3.

Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.

Love WE, Bernhard JD, Bordeaux JS.

Arch Dermatol. 2009 Dec;145(12):1431-8. doi: 10.1001/archdermatol.2009.291. Review.

PMID:
20026854
4.

Treatment of cutaneous tumors with topical 5% imiquimod cream.

Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C.

Clinics (Sao Paulo). 2009;64(10):961-6. doi: 10.1590/S1807-59322009001000005.

5.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
6.

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.

Clin Cancer Res. 2006 Sep 1;12(17):5165-73.

7.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

8.

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ.

BMC Cancer. 2011 Nov 30;11:505. doi: 10.1186/1471-2407-11-505.

9.

Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?

Höcker B, Tönshoff B.

Paediatr Drugs. 2011 Feb 1;13(1):49-69. doi: 10.2165/11538530-000000000-00000. Review.

PMID:
21162600
10.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.

Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8.

11.

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA.

Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20.

PMID:
20890178
12.

Everolimus in clinical practice in long-term liver transplantation: an observational study.

Casanovas T, Argudo A, Peña-Cala MC.

Transplant Proc. 2011 Jul-Aug;43(6):2216-9. doi: 10.1016/j.transproceed.2011.06.015.

PMID:
21839237
13.

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

Gabardi S, Baroletti SA.

Pharmacotherapy. 2010 Oct;30(10):1044-56. doi: 10.1592/phco.30.10.1044. Review.

PMID:
20874042
14.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.

Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N; Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network.

Haematologica. 2012 Jul;97(7):1085-91. doi: 10.3324/haematol.2011.053173. Epub 2012 Feb 7.

15.

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.

Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W.

Ann N Y Acad Sci. 2013 Jul;1291:14-32. doi: 10.1111/nyas.12122. Epub 2013 May 9. Review.

PMID:
23659703
16.

Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.

Micali G, De Pasquale R, Caltabiano R, Impallomeni R, Lacarrubba F.

J Dermatolog Treat. 2002 Sep;13(3):123-7.

PMID:
12227875
17.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I.

J Clin Oncol. 2008 Apr 1;26(10):1588-95. doi: 10.1200/JCO.2007.14.0988. Epub 2008 Mar 10.

18.

Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.

Mirza B, De'Ambrosis B.

Clin Exp Dermatol. 2003 Nov;28 Suppl 1:16-8.

PMID:
14616806
19.

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.

Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.

Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.

20.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA.

Cancer. 2007 Aug 1;110(3):599-605.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk